LRFN3-FXYD7 Fusion FISH Probe
The LRFN3-FXYD7 Fusion FISH Probe is used to confirm a fusion of the LRFN3 and FXYD7 genes. The fusion of the LRFN3 and FXYD7 genes has been associated with Esophageal Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| LRFN3-FXYD7-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-RERE | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-REOR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-REGO | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-REGR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-OROR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GORE | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GROR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| LRFN3-FXYD7-20-AQAQ | 20 (40 μL) | 200 μL |
|
FXYD7 Gene Summary
This reference sequence was derived from multiple replicate ESTs and validated by similar human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. This gene product, FXYD7, is novel and has not been characterized as a protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu., Dec 2000]
Gene Name: FXYD Domain Containing Ion Transport Regulator 7
Chromosome: CHR19: 35634153 -35645205
Locus: 19q13.12
LRFN3 Gene Summary
The Leucine Rich Repeat And Fibronectin Type III Domain Containing 3 (LRFN3) gene is located on chr19 :36428021-36436097 at 19q13.12.
Gene Name: Leucine Rich Repeat And Fibronectin Type III Domain Containing 3
Chromosome: CHR19: 36428021 -36436097
Locus: 19q13.12
Gene Diseases
The LRFN3 FXYD7 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Esophageal Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|